For a biotech, your intellectual property is your most prized asset. | For a biotech, your intellectual property is your most ...

Global investment giant KKR has launched Allyntra as a new, precision-engineered solutions platform for the medtech industry ...

Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to elevate them to “priority asset ...

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The readouts expand the evidence on one of two oral weight-loss drugs in development at Kailera. The biotech is also ...

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...

IHealthScreen hauled in FDA 510(k) clearance for its AI-powered diagnostic that detects mild diabetic retinopathy in diabetic ...

Roche has halted development on two of its Huntington’s disease prospects, delivering another blow to a patient community that has long awaited new medicines. The Swiss drugmaker explained its ...

Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...

The Advanced Research Projects Agency for Health (ARPA-H) has awarded a new tranche of funds for companies and institutions ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...